The analysis of approaches to conducting bioequivalence studies and the policy of “transparency” of their results in Ukraine, the United States and the European Union
DOI:
https://doi.org/10.24959/cphj.21.1548Keywords:
generic drugs, drug registration, bioequivalence studies, transparency policyAbstract
Providing the population of Ukraine with quality, effective and, at the same time, economically affordable medicines is a priority task of the healthcare system. Taking into account the relatively low cost of their development generic drugs are available to the majority of the country’s population; thus, bioequivalence studies are needed to obtain data on their efficacy and safety. Ukraine is currently in the process of harmonizing domestic regulatory requirements for generic drugs and conducting bioequivalence studies with global ones. Therefore, it is important to find out the differences in approaches to the registration of generics and studies of their bioequivalence in Ukraine and other countries. Another important aspect is to provide the policy of “transparency” of bioequivalence research results, which contributes to the use of better drugs.
Aim. To analyze domestic and global approaches to the organization of the bioequivalence research and provide the policy of “transparency” of their results.
Materials and methods. A comparative analysis of approaches to drug registration, requirements for generic drugs and bioequivalence studies and ways to provide the policy of “transparency” of their results in Ukraine, the United States and the European Union was conducted.
Results. The analysis has revealed that the methods of registration of drugs in Ukraine, the United States and the EU are the same. Approaches to providing the “transparency” of the results of bioequivalence studies differ since in Ukraine the publication of such information is not mandatory and is at the discretion of pharmaceutical manufacturers.
Conclusions. Domestic regulatory requirements for assessing generic drugs are harmonized with the world ones. Today, there is a need to introduce a mandatory requirement for the publication of bioequivalence studies, and it will contribute to providing an effective “transparency” policy.
References
Lira, C. A., Oliveira, J. N., Mdos, A. S., Vancini-Campanharo, C. R., Vancini, R. L. (2014). Knowledge, perceptions and use of generic drugs: a cross sectional study. Einstein (Sao Paulo), 12 (3), 267–273. doi: 10.1590/s1679-45082014ao3125.
European Medicines Agency. ema.europa.eu. Available at: http://www.ema.europa.eu.
World Health Organisation. who.int. Available at: http://www.who.int/.
Guideline for Good Clinical Practice E6 (ICH E6: Good Clinical Practice: Consolidated guideline, CPMP/ICH/135/95).
Food and Drug Administration. fda.gov. Available at: http://www.fda.gov.
MOZ Ukrainy. (2009). Nastanova ST-N 42-7.0:2008 «Likars`ki zasoby`. Nalezhna klinichna prakty`ka». Kyiv, 48.
MOZ Ukrainy. (2017). Nastanova ST-N 42-7.3:2020 «Likars`ki zasoby`. Doslidzhennia bioekvivalentnosti». Kyiv, 92.
MOZ Ukrainy. (2005). Nakaz № 426 vid 26.08.2005 roku «Pro zatverdzhennia Poriadku provedennia ekspertyzy reiestratsiinykh materialiv na likars`ki zasoby`, shho podaiutsia na derzhavnu reiestratsiiu (perereiestratsiiu), a takozh ekspertyzy materialiv pro vnesennia zmin do reiestratsiinykh materialiv protiahom dii reiestratsiinoho posvidchennia». zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/laws/show/z1069-05#Text.
MOZ Ukrainy. (2009). Nakaz № 690 vid 23.09.2009 roku «Pro zatverdzhennia Poriadku provedennia klinichnykh vyprobuvan likarskykh zasobiv ta ekspertyzy materialiv klinichnykh vyprobuvan i Typovoho polozhennia pro komisii z pytan etyky». Available at: https://zakon.rada.gov.ua/laws/show/z1010-09#Text.
Zupanets, I., Usenko, V, Kriachok, I., Kosiachenko, K., Strashnyi, V., Savych, S., Tarasenko, O. (2017). Farmatsevt-praktyk, 6, 10–14. Available at: https://fp.com.ua/articles/klasyfikatsiya-likarskyh-zasobiv-na-pidstavi-yihnoyi-ekvivalentnosti/.
Zupanets, I. A. (2017). Suchasni pryntsypy otsinky ekvivalentnosti likarskykh zasobiv v Ukraini: metodychni rekomendatsii. Kyiv, 26.
Zupanets, I. A., Starchenko, M. H., Dobrova, V. Ye. (2011). Zaporozhskyi medytsynskyi zhurnal, 13 (4), 23–27.
Zupanets, K. O., Dobrova, V. Ye. (2016). Klinichna farmatsiia, 20 (1), 26–32.
Alfonso-Cristancho, R., Andia, T., Barbosa, T., Watanabe, J. H. (2015). Definition and Classification of Generic Drugs Across the World. Appl Health Econ Health Policy, 13 (1), 5-11. doi: https://doi.org/10.1007/s40258-014-0146-1.
Vacca, C., Vargas, C., Cañás, M., Reveiz, L. (2011). Publicidad y promocion de medicamentos: regulaciones y grado de acatamientoen cinco paıґses de America Latina; Drug advertising and promotion: regulations and extent of compliance in five Latin American countries. Rev panam salud pґublica, 29 (2), 76–83.
Directive 2004/24/EC of the European Parliament and the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. (2004). Official Journal of the European Union., 136, 85–90. Available at: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/directive-2001/83/ec-european-parliament-council-6-november-2001-community-code-relating-medicinal-products-human-use_en.pdf.
Nagadurga, D. H. (2019). Bioavailability and Bioequivalence Studies. Pharmaceutical Formulation Design-Recent Practices. IntechOpen, 71. doi: https://doi.org/10.5772/intechopen.85145.
Vokinger, K. N., Kesselheim, A. S., Avorn, J., Sarpatwari, A. Strategies That Delay Market Entry of Generic Drugs. Health care policy and law. JAMA Intern Med., 177 (11), 1665–1669. doi: 10.1001/jamainternmed.2017.4650.
Jalali, R. K., Deepa, R. (2018). Generic Drug and Bioequivalence Studies. Pharmaceutical Medicine and Translational Clinical Research. Academic Press, 327-339. doi: https://doi.org/10.1016/B978-0-12-802103-3.00021-3.
Zhao, L., Kim, M.-J., Zhang, L., Lionberger, R. (2019). Generating Model Integrated Evidence for Generic Drug Development and Assessment. Clinical Pharmacology & Therapeutics. Generic Drugs, 105 (2), 338–349. doi: https://doi.org/10.1002/cpt.1282.
Alfonso-Cristancho, R., Andia, T., Barbosa, T., Watanabe, J. H. (2015). Definition and Classification of Generic Drugs Across the World. Appl Health Econ Health Policy, 13 (1), 5-11. doi: https://doi.org/10.1007/s40258-014-0146-1.
Galgatte, U. C., Jamdade, V. R., Aute, P. P., Chaudhari, P. D. (2014). Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada. Saudi Pharmaceutical Journal, 22, 391-402. doi: https://doi.org/10.1016/j.jsps.2013.05.001.
Zhao, L., Kim, M. J., Zhang, L., Lionberger, R. (2019). Generating Model Integrated Evidence for Generic Drug Development and Assessment. Clin. Pharmacol. Ther., 105 (2), 338-349. doi: https://doi.org/10.1002/cpt.1282.
Manzoli, L., Flacco, M. E., Boccia, S., D’Andrea, E., Panic, N., Marzuillo, C. et al. (2015). Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol., 15, 351-368. doi: https://doi.org/10.1007/s10654-015-0104-8.
Zupanets, I. A., Chernykh, V. P. (Eds.). (2019). Rx index® – Dovidnyk ekvivalentnosti likarskykh zasobiv. 3rd ed. Kyiv: Farmatsevt Praktyk, 832.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
